Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
VivoPower's (VVPR) Tembo E-LV Executes a Definitive Merger Agreement with Cactus Acquisition Corp. 1 (CCTS)
-
Tembo E-LV, a subsidiary of Nasdaq-listed VivoPower International PLC (“VVPR”) executes a definitive Business Combination Agreement with CCTS for a combined enterprise value of US$904 million
-
Flamingo Therapeutics Announces Participation in Upcoming Investor Conferences
-
Editas Medicine to Participate in Upcoming Investor Conferences
-
Prime Medicine to Participate in Upcoming Investor Conferences
-
Vor Bio to Participate in Upcoming Investor Conferences
-
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
-
Allurion Technologies (ALUR) PT Lowered to $2.50 at Chardan Capital Markets
-
Chardan Capital Markets Starts Clearside Biomedical (CLSD) at Buy
-
Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Avidity Biosciences Inc. (RNA) Prices Upsized 7.32M Share Offering at $41/sh
-
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
-
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
-
Chardan Capital Markets Assumes Zura Bio Ltd. (ZURA) at Buy
-
Adagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac Arrhythmias
-
Chardan Capital Markets Assumes MeiraGTx Holdings plc (MGTX) at Buy
-
Pershing Square USA, Ltd. Announces Proposed IPO Size
-
Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
-
Gateway Group Announces Preliminary Sponsors and Additional Presenting Companies for September Gateway Conference
-
Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”
-
ReShape Lifesciences Inc. (RSLS) to Merge with Vyome Therapeutics, Enters Asset Purchase Agreement With Biorad Medisys
-
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
-
Pershing Square USA, Ltd. Announces Launch of IPO Roadshow
-
Chardan Capital Markets Starts Cargo Therapeutics (CRGX) at Buy
-
Eyenovia Inc (EYEN) Prices 7.56M Share Offering at $0.66/sh
-
Eyenovia Announces Pricing of $5M Registered Direct Offering
-
Form SC 13G ANEW Medical, Inc. Filed by: CHARDAN CAPITAL MARKETS LLC
-
ANEW MEDICAL, INC. and REDWOOD ACQUISITION CORP. ANNOUNCE CLOSING OF THEIR BUSINESS COMBINATION
-
TechMediaBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Management Presents During Chardan Transport Platform Tech Series
-
TechMediaBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Completes Presentation at Chardan Transport Platform Tech Series
-
Freight Technologies Inc. Participates in Chardan's Transport Platform Tech Series
-
Chardan Capital Markets Starts Cognition Therapeutics (CGTX) at Buy
-
AtlasClear Holdings, Inc. Announces First Quarter 2024 Financial Results
-
Chardan Capital Markets Starts iBio, Inc. (IBIO) at Buy
-
Sonnet BioTherapeutics (SONN) Announces Review of Strategic Alternatives
-
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
-
AB Science reports its revenues for the year 2023 and provides an update on its activities
-
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
-
Xtribe, Technology-driven Geolocation-based Commerce Platform, to Go Public on Nasdaq through Proposed Business Combination with WinVest Acquisition Corp. (NASDAQ: WINV)
-
GenSight Biologics Announces a Successful Offering for an Amount Over €9.2 Million
-
Surf Air Mobility Participates in Chardan’s Virtual Transport Platform Tech Series
-
Iovance Biotherapeutics to Present at Upcoming Conferences
-
MeiraGTx to Participate in Upcoming Investor Conferences
-
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Chardan Capital Markets Assumes Prime Medicine (PRME) at Buy
-
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Myeloid Therapeutics to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Form X-17A-5 CHARDAN CAPITAL MARKETS For: Dec 31
-
Chardan Capital Markets Downgrades Energy Vault Holdings Inc. (NRGV) to Sell

